The Biosensors International Group is introducing new range of BioMatrix products in the Indian market. At present, the company is conducting the Stealth clinical trials to support regulatory approval of BioMatrix drug euting stent (DES) system, which incorporates S-Stent, Senso stent delivery catheter, proprietary bioresorbable polymer and proprietary anti-restenotic drug namely Biolimus A-9.The company has applied for CE Mark application for its BioMatrix system.

BioMatrix is mounted on a low- profile rapid exchange delivery system enabling access to even to most difficult lesions and vessel physiologies. In combination with proprietary drug, Biolimus A9, DES has a bioresorable polymer, which is completely co-released with the drug, reaching therapeutic concentrations when the cells are proliferating.

"Biolimus A9 is the anti-restenotic drug specifically engineered for use on stents. It is cytostatic that exhibits powerful anti proliferative, anti- inflammatory and anti- migratory effect reducing the restenosis side- effect. After the drug and polymer co- release, only our proven bare metal S- stent and an ultra- thin biocompatible primer coating remain, allowing for optimal vessel healing," said the sources.

The unique proprietary polymer developed by the company is differentiated from competitive polymers because of its bioresorbable property. The bioresorbable polymer degrades to water and carbon dioxide as the drug is released, mitigating side effects such as inflammation or polymer flaking, they added.